SynthesisFrontiers in pharmacology2025
8 specific Chinese herbal injections combined with chemotherapy for breast cancer: a systematic review and network meta-analysis of comparative safety and efficacy.
Synthesis in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Breast cancer (BC) poses a major threat to human health. Since the beginning of the 21st century, numerous clinical studies conducted in China have reported the therapeutic advantages of combining Chinese herbal injections (CHIs) with chemotherapy; however, comparative evaluations of different CHIs remain scarce. This multidimensional network meta-analysis was designed to compare the efficacy of various CHIs and to identify the optimal combination regimen of CHI plus chemotherapy for breast cancer treatment. Methods: By searching multiple databases, we screened randomized controlled trials (RCTs) on Chinese herbal injections (CHIs) combined with chemotherapy interventions for breast cancer (BC) from database inception to 25 October 2024. Studies meeting inclusion criteria with methodologically sound quality were included. Data analysis was performed using Stata 17.0 and R 4.2.1 software, with odds ratio (OR) and standardized mean difference (SMD) as effect size measures. The surface under the cumulative ranking curve (SUCRA) method was applied to rank the evaluated treatment regimens. Results: This network meta-analysis included 44 eligible RCTs, involving 3,982 patients and 8 CHIs. Shenqifuzheng Injection (SQFZ) combined with chemotherapy was most effective in enhancing the efficacy of chemotherapy, improving the quality of life of breast cancer patients, ameliorating the CD4+/CD8+ T-cell ratio, and inhibiting the decrease in white blood cell (WBC) count after chemotherapy. Compound Sophora Injection (FFKS) combined with chemotherapy performed best in increasing post - chemotherapy CD4 Systematic Review Registration: https://www.crd.york.ac.uk/PROSPERO/myprospero, identifier [CRD42024589306].
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.